Soleno Therapeutics Enters Material Definitive Agreement
Ticker: SLNO · Form: 8-K · Filed: Dec 17, 2024 · CIK: 1484565
| Field | Detail |
|---|---|
| Company | Soleno Therapeutics Inc (SLNO) |
| Form Type | 8-K |
| Filed Date | Dec 17, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.001, $200 million, $50.0 million, $100.0 million, $50 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, financial-obligation
TL;DR
SOLENO just signed a big deal, could be good or bad for cash.
AI Summary
On December 17, 2024, Soleno Therapeutics, Inc. entered into a material definitive agreement, likely related to its financial obligations. The company, formerly known as Capnia, Inc., is incorporated in Delaware and headquartered in Redwood City, California.
Why It Matters
This filing indicates a significant contractual development for Soleno Therapeutics, which could impact its financial standing and future operations.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new financial obligations or opportunities, carrying inherent risks until their full implications are understood.
Key Numbers
- 001-36593 — SEC File Number (Identifies the company's filings with the SEC.)
- 77-0523891 — IRS Employer Identification Number (Company's tax identification number.)
Key Players & Entities
- Soleno Therapeutics, Inc. (company) — Registrant
- Capnia, Inc. (company) — Former company name
- Delaware (jurisdiction) — State of incorporation
- Redwood City, CA (location) — Business address
- December 17, 2024 (date) — Date of earliest event reported
FAQ
What specific material definitive agreement did Soleno Therapeutics enter into?
The filing states that the company entered into a 'Material Definitive Agreement' but does not specify the details of the agreement in the provided text.
What is the nature of the financial obligation or off-balance sheet arrangement mentioned?
The filing indicates the creation of a 'Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant,' but the specific details are not provided in this excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported is dated December 17, 2024.
What was Soleno Therapeutics' former company name?
Soleno Therapeutics, Inc. was formerly known as Capnia, Inc.
Where is Soleno Therapeutics, Inc. headquartered?
Soleno Therapeutics, Inc. is headquartered at 100 Marine Parkway, Suite 400, Redwood City, CA 94065.
Filing Stats: 1,299 words · 5 min read · ~4 pages · Grade level 12.6 · Accepted 2024-12-17 16:30:52
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value SLNO NASDAQ Indicate by
- $200 million — an aggregate principal amount of up to $200 million. Pursuant to the Loan Agreement, the
- $50.0 million — the Loan Agreement, the Borrowers drew $50.0 million in an initial loan tranche on the Closi
- $100.0 million — wers have access to up to an additional $100.0 million of loan proceeds in three additional tr
- $50 million — earlier of the date that the more than $50 million principal amount of term loans have bee
Filing Documents
- d903020d8k.htm (8-K) — 31KB
- d903020dex991.htm (EX-99.1) — 7KB
- g903020g87d77.jpg (GRAPHIC) — 4KB
- 0001193125-24-280509.txt ( ) — 169KB
- slno-20241217.xsd (EX-101.SCH) — 3KB
- slno-20241217_lab.xml (EX-101.LAB) — 18KB
- slno-20241217_pre.xml (EX-101.PRE) — 11KB
- d903020d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. SOLENO THERAPEUTICS, INC. Date: December 17, 2024 By: /s/ Anish Bhatnagar Anish Bhatnagar Chief Executive Officer